Radiotherapy-Enhancing Cancer Nanomedicine Secures Good Phase II/III Results

A nanomedicine designed to help amplify and focus radiation treatment on hard to treat soft tissue sarcoma cells has achieved positive Phase II/III trial results for French-American biotech Nanobiotix.“Data are exceptional and show without any doubt an improvement of radiation therapy impact,” commented Sylvie Bonvalot, Head of Sarcoma and Complex Tumor Surgery Unit at Institut Curie, Paris, who was a Principal Investigator for the trial. “This innovation will play a role in many other indications and particularly where radiotherapy is used alone.”